BR112018014771A2 - composição compreendendo extrato de proteoglicanos de algas e seu uso - Google Patents

composição compreendendo extrato de proteoglicanos de algas e seu uso

Info

Publication number
BR112018014771A2
BR112018014771A2 BR112018014771A BR112018014771A BR112018014771A2 BR 112018014771 A2 BR112018014771 A2 BR 112018014771A2 BR 112018014771 A BR112018014771 A BR 112018014771A BR 112018014771 A BR112018014771 A BR 112018014771A BR 112018014771 A2 BR112018014771 A2 BR 112018014771A2
Authority
BR
Brazil
Prior art keywords
composition
proteoglycan extract
algal proteoglycan
algal
extract
Prior art date
Application number
BR112018014771A
Other languages
English (en)
Inventor
Qi Qing
Original Assignee
Qi Qing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qi Qing filed Critical Qi Qing
Publication of BR112018014771A2 publication Critical patent/BR112018014771A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de um extrato de proteoglicanos de algas e uma composição compreendendo o mesmo na fabricação de um medicamento para tratar ou prevenir tumor, dor, inflamação ou doenças mediadas por fatores inflamatórios.
BR112018014771A 2016-01-20 2017-01-20 composição compreendendo extrato de proteoglicanos de algas e seu uso BR112018014771A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610037244 2016-01-20
PCT/CN2017/071861 WO2017125065A1 (en) 2016-01-20 2017-01-20 A composition comprising an algal proteoglycan extract and use thereof

Publications (1)

Publication Number Publication Date
BR112018014771A2 true BR112018014771A2 (pt) 2018-12-11

Family

ID=59361475

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014771A BR112018014771A2 (pt) 2016-01-20 2017-01-20 composição compreendendo extrato de proteoglicanos de algas e seu uso

Country Status (12)

Country Link
US (5) US10729743B2 (pt)
EP (1) EP3405206B1 (pt)
JP (4) JP7022701B2 (pt)
KR (1) KR20180102602A (pt)
CN (4) CN110538202A (pt)
AU (1) AU2017209342C1 (pt)
BR (1) BR112018014771A2 (pt)
CA (1) CA3011632A1 (pt)
HK (1) HK1256287A1 (pt)
RU (1) RU2739558C2 (pt)
WO (1) WO2017125065A1 (pt)
ZA (1) ZA201804744B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109758467B (zh) * 2019-03-08 2020-12-25 中国农业科学院兰州兽医研究所 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952298A (en) * 1993-12-21 1999-09-14 The University Of Hawaii Cryptophycins
US5709855A (en) 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
CN1098707C (zh) * 1999-07-19 2003-01-15 齐清 含藻蛋白多糖提取物的药物组合物以及藻蛋白多糖的提取
JP2005318878A (ja) * 2004-05-07 2005-11-17 Hideyo Sasaya 健康食品
CN106110041A (zh) * 2016-08-25 2016-11-16 鄢海军 一种应用少儿惊风大脑神经元平衡的洗发膏

Also Published As

Publication number Publication date
CN110507675A (zh) 2019-11-29
EP3405206A4 (en) 2019-11-20
US10729743B2 (en) 2020-08-04
JP7373530B2 (ja) 2023-11-02
JP7273117B2 (ja) 2023-05-12
CA3011632A1 (en) 2017-07-27
KR20180102602A (ko) 2018-09-17
JP2019502760A (ja) 2019-01-31
RU2018128373A3 (pt) 2020-03-11
JP2022003034A (ja) 2022-01-11
US20200376076A1 (en) 2020-12-03
AU2017209342B2 (en) 2023-09-21
US11648288B2 (en) 2023-05-16
EP3405206B1 (en) 2024-03-20
HK1256287A1 (zh) 2019-09-20
US20200338159A1 (en) 2020-10-29
RU2739558C2 (ru) 2020-12-25
CN110507676A (zh) 2019-11-29
AU2017209342A1 (en) 2018-08-16
CN108472323A (zh) 2018-08-31
EP3405206A1 (en) 2018-11-28
JP2022003035A (ja) 2022-01-11
JP2022003036A (ja) 2022-01-11
AU2017209342C1 (en) 2024-01-25
CN110538202A (zh) 2019-12-06
US20200360470A1 (en) 2020-11-19
US20230241160A1 (en) 2023-08-03
JP7022701B2 (ja) 2022-02-18
CN108472323B (zh) 2019-11-08
US11389503B2 (en) 2022-07-19
US11464826B2 (en) 2022-10-11
JP7273118B2 (ja) 2023-05-12
RU2018128373A (ru) 2020-02-20
WO2017125065A1 (en) 2017-07-27
ZA201804744B (en) 2019-04-24
US20190022177A1 (en) 2019-01-24
EP3405206C0 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201800199A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CO2019012080A2 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CL2015002658A1 (es) Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio
BR112017008344A2 (pt) extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica.
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
CR20160561A (es) Variantes del anticuerpo anti-factor d y sus usos
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
EA202090270A1 (ru) Новые замещенные производные ксантина
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
BR112018014771A2 (pt) composição compreendendo extrato de proteoglicanos de algas e seu uso
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]